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Abstract
Objective: to explore the association between genetic markers and Oligoclonal Bands (OCB) in the Cerebro Spinal Fluid
(CSF) of Italian Multiple Sclerosis patients.
Methods: We genotyped 1115 Italian patients for HLA-DRB1*15 and HLA-A*02. In a subset of 925 patients we tested
association with 52 non-HLA SNPs associated with MS susceptibility and we calculated a weighted Genetic Risk Score.
Finally, we performed a Genome Wide Association Study (GWAS) with OCB status on a subset of 562 patients. The best
associated SNPs of the Italian GWAS were replicated in silico in Scandinavian and Belgian populations, and meta-analyzed.
Results: HLA-DRB1*15 is associated with OCB+: p = 0.03, Odds Ratio (OR) = 1.6, 95% Confidence Limits (CL) = 1.1–2.4. None of
the 52 non-HLA MS susceptibility loci was associated with OCB, except one SNP (rs2546890) near IL12B gene (OR: 1.45; 1.09–
1.92). The weighted Genetic Risk Score mean was significantly (p = 0.0008) higher in OCB+ (7.668) than in OCB2 (7.412)
patients. After meta-analysis on the three datasets (Italian, Scandinavian and Belgian) for the best associated signals resulted
from the Italian GWAS, the strongest signal was a SNP (rs9320598) on chromosome 6q (p = 9.461027) outside the HLA
region (65 Mb).
Discussion: genetic factors predispose to the development of OCB.
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Introduction
The presence of oligoclonal bands (OCB) in the Cerebro Spinal
Fluid (CSF) is a distinctive hallmark of Multiple Sclerosis (MS),
found in 48 to 100% of patients in European populations [1]. The
presence of a genetic influence on the OCB phenotype is suggested
by its association, in several populations, with HLA-DRB1*15,
which is also the strongest genetic susceptibility factor for the
development of the disease. The Odds Ratio (OR) for OCB
positivity ranges from 1.6 [2] to 3.4 [3], not dissimilarly from the
OR observed for disease susceptibility. In spite of this indication
and of all the efforts undertaken in the study of MS genetic
susceptibility, the genetic association with the OCB phenotype was
not extensively investigated so far. We aimed to explore the
association between OCB and other genetic markers in Italian MS
patients, both with a classical unbiased, genome-wide strategy and
with a special attention for known MS susceptibility markers. This
approach was worth attempting given the preliminary data on
HLA-DRB1*15. We utilized an Italian population as a discovery
sample for genome-wide study, and replicated the new findings in
independent European cohorts from Scandinavia and Belgium.
Materials and Methods
Ethics Statement
The PROGEMUS study was approved by the Ethical
Committee of the AOU Maggiore della Carita`, Novara (Coordi-
nating Centre) and those of the following Institutions: IRCCS
Fondazione Ca` Granda, Ospedale Maggiore Policlinico, Milan,
Fondazione Istituto Neurologico C. Mondino-IRCCS, Pavia,
ASO S. Luigi Gonzaga, Orbassano, Fondazione Don C.Gnocchi,
IRCCS S. Maria Nascente, Milan, AO S. Croce e Carle, Cuneo,
AUSL Valle d’Aosta, Aosta, AOU S.Giovanni Battista, Turin,
ASL-TO2, Turin, AOU Integrata, Verona, AO S. Andrea, Rome,
Italy. The PROGRESSO study was approved by the Ethical
Committee of the San Raffaele Hospital, Milano (Coordinating
Centre) and those of the following Institutions: AO Spedali Civili,
Brescia, AO S. Antonio Abate, Gallarate, San Carlo Hospital,
Potenza, Italy. The Danish study was approved by the Danish
Ethical Committee Review Board for Copenhagen and Frederiks-
berg/today The Capital Region of Denmark. The Norwegian
study was approved by The Regional Committee for Medical and
Health Research Ethics (REC)- South East and REC West,
Norway. The Swedish study was approved by the Regional Ethical
Review Board in Stockholm. The Belgian study was approved by
the Commissie Medische, Ethiek/Toetsingscommissie University
Hospital, Leuven. All individuals involved in this study signed a
written informed consent.
Patients
A total of 1347 consecutive Italian MS patients diagnosed
according to McDonald criteria [4], were ascertained by two
Italian consortia, PROGEMUS (N = 1002), and PROGRESSO
(N = 345). Patients born in Sardinia, of non-Italian ancestry, or
refusing permission to DNA testing were not ascertained. A
lumbar puncture was performed in 1115 patients (83% of the
original cohort), 731 women and 384 men. Excluded patients
(N = 232) were not statistically different from those included with
regards to gender, clinical form (bout onset vs. primary
progressive), age at onset, and MSSS [5] (data not shown). OCB
positivity (OCB+) was defined as two or more bands present in
CSF but absent in plasma at the same point in time. When two
CSF analyses were performed, we considered the result of the last
one. In Italy, OCB were assessed in laboratories pertaining to the
network of Italian certified Neuroimmunology Laboratories and
analyzed by isoelectric focusing and immunodetection of IgG. In
Belgium, Norway and Sweden (apart from Stockholm hospitals)
Table 1. Clinical characteristics of MS patients according to OCB status in the three populations.
Characteristic OCB negative OCB positive
Italy Belgium Scandinavia Italy Belgium Scandinavia
N (%) 150 (13%) 39 (11%) 168 (11%) 965 (87%) 317 (89%) 1406 (89%)
Male/female ratio 0.81 0.95 0.51 0.76 0.47 0.39
% PP – MS 15% 18% 10% 19% 12% 9%
Mean age at onset 33.8 36.1 34.7 31.7 33.3 33.0
Mean [14] 2.7 4.6 2.9 3.3 4.4 2.9
Mean MSSS [15] 3.9 5.5 4.0 4.2 5.4 3.9
Abbreviations: PP = Primary Progressive, OCB = oligoclonal bands, EDSS = Expanded disability status scale, MSSS = Multiple sclerosis severity score.
doi:10.1371/journal.pone.0064408.t001
Figure 1. Distribution of the wGRS in MS patients positive
(OCB+) or negative (OCB2) for OCB. wGRS (weighted Genetic Risk
Score) has been calculated using the ORs for the 52 non-HLA MS
susceptibility variants,6 and three HLA alleles (DRB1*15, DRB1*03 and
A*02). The reported p value derived from the comparison of the mean
wGRS (Student’s t test) in OCB+ vs OCB2.
doi:10.1371/journal.pone.0064408.g001
Genetic Markers of CSF Oligoclonal Bands in MS
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e64408
CSF analysis was performed with agar electrophoresis before
2000–2 and with isoelectric focusing thereafter. In the Stockholm
area, CSF analysis was done according to Olsson et al. [6]. All the
samples and the clinical information were collected after written
informed consent. The clinical characteristics of the Italian,
Belgian, and Scandinavian MS patient samples are described in
Table 1.
Genetic analysis
a) overview
HLA-DRB1*15 and HLA-A*02 genotyping was performed in
1115 Italian patients, as previously described [7]. DRB1*03
genotypes were imputed by HLA*IMP software [8]. We tested
925 patients (814 OCB+, 111 OCB2) for association with the 52
non-HLA SNPs, shown to be associated with MS susceptibility in
the recent large IMSGC-WTCCC2 genome wide association
study (GWAS) [9]. In the same Italian group we calculated a
weighted Genetic Risk Score (wGRS), as described by De Jager
[10], using the ORs [9] for the 52 non-HLA MS susceptibility
variants, and three HLA alleles (DRB1*15, DRB1*03 and A*02).
Finally, we performed a GWAS with OCB status on the subset of
Italian patients from the IMSGC-WTCCC GWAS study [9]. This
sample included 562 (513 OCB+ and 49 OCB2) patients,
genotyped with the Illumina 660-Quad platform. After quality
control (QC) filtering [9], there were 504967 SNPs remaining.
The genomic inflation factor was 1.009. The same (QC) filtering
[9] has been applied to the Scandinavian and Belgium datasets.
The association of each of the above markers with OCB status was
evaluated comparing the allele frequency in OCB+ vs. OCB2
patients. All GWAS statistical analyses (QC, association and meta-
analysis) were performed with PLINK software.
b) Statistical and computational details
wGRS calculation: The wGRS was formulated according to De
Jager et al. [10] using the following model: wGRS =S (nrisk alleles *
lnOR). We used a total of 55 genetic risk loci (3 HLA and 52 non-
HLA loci). The 52 non-HLA loci included 23 well known MS loci,
previously identified in several large-scale association studies and
validated in the recent IMSGC and WTCCC GWAS [table S2 in
reference 9], and 29 new loci, whose association with MS have
been reported for the first time in the same GWAS [table S3 in
reference 9]. The 3 HLA markers were classical HLA alleles
(namely HLA-DRB1*15:01, HLA-DRB1*03:01 and HLA-
A*02:01) showing a well established association with MS. For
each marker, the OR used in the model is the allelic OR from
IMSGC and WTCCC GWAS, discovery plus validation set [9].
c) GWAS analysis
Quality Controls (QC) on the GWAS data for all datasets were
performed utilizing the filters reported in reference 9. Briefly, for
individual QC: call rates .92.5%, relatedness ,5% IBD (Identity
by descent), for SNP QC: MAF.0.10, call rate .0.90, Hardy-
Weinberg .10250.
Figure 2. Results of the GWAS for OCB status and meta-analysis after in silico replication. (a) Manhattan Plot of the GWAS performed in
the Italian OCB+ vs OCB2 MS patients, as a discovery dataset. The blue horizontal line indicates the threshold of p values arbitrarily chosen to select
the ‘‘best associated SNPs’’ (p-value,1024, 89 SNPs) to perform in silico replication (Table S1) using data from Scandinavia and Belgium populations.
(b) Meta-analysis for the rs9320598 SNP, the strongest signal after the meta-analysis of the combined results of all datasets (Italy, Scandinavia and
Belgium). The forest plot summarizes the results obtained for the discovery Italian dataset, for the replication datasets from Scandinavia and Belgium,
and the combined analysis calculated using the random and fixed-effect method.
doi:10.1371/journal.pone.0064408.g002
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d) GWAS analysis: Association and Meta-Analysis
Basic association testing was performed with the command line:
plink – assoc – ci 0.95– reference-allele ,file.txt.. To select the
covariates to be used in a logistic analysis, we checked the
following potential confounders or interactors in the discovery
dataset from the Italian population: gender, age of onset and MS
clinical subtype (Primary Progressive vs. Bout Onset) for associ-
ation with OCB status, using basic Chi-square test (for gender and
clinical subtype) or Student’s T test (for age of onset). None of
these factors was differentially distributed in OCB+ vs. OCB2
patients, therefore none of these variables were selected as
covariates.
Population stratification was evaluated both with the Genomic
Control calculation (l), and by means of the quantile-quantile
distribution. The lwas evaluated with PLINK, by adding – adjust
to the basic association command line. The quantile-quantile
distribution was visually analysed by Q–Q plot, generated by the
R software (Figure S1) The genomic inflation factor (l) was very
low (1.009), indicative of a reduced population stratification. This
is confirmed also by the quantile-quantile distribution (Figure S1).
On these bases, and on the bases of the previous analysis on
covariates, we decided not to add Principal Components in our
model, and therefore not to implement a logistic analysis. The
Manhattan plot was created with the software Haploview,
providing the.assoc file.
Genetic and clinical data for Scandinavian and Belgian patients
were analyzed with a similar pipeline.
Meta-analysis was performed with PLINK software, basic
option (string: plink – meta-analysis), that uses, for all datasets,
the following information: SNP ID, chromosome, position, alleles,
OR, standard error of OR and p-value. We calculated ORs and p-
values using both fixed and random effects models (reported in
Table S1). Forest plot was instead created with R software, library
‘‘meta’’.
Results
Our results confirm that HLA DRB1*15 is positively associated
with OCB+ (p = 0.03 OR = 1.6; 95%CL = 1.1–2.4); 313 patients
were DRB1*15+/OCB+, 35 DRB1*15+/OCB2, 652
DRB1*152/OCB+, and 115 DRB1*152/OCB2. None of the
52 non-HLA MS susceptibility loci (Table S2) was associated with
OCB status, except one SNP (rs2546890) near IL12B gene, with
the MS risk allele conferring an OR of 1.45 (95% CL 1.09–1.92)
for OCB positivity (p = 0.010). However, the combined effect of
these markers plus three HLA MS risk alleles (DRB1*15, DRB1*03
and A*02) on OCB status (evaluated constructing a wGRS) was
significant. In fact, the wGRS mean was significantly (p = 0.0008)
higher in OCB+ (7.668) than in OCB2 (7.412) patients (Figure 1)
even after removing DRB1*15 (p = 0.0096). After removing the
three HLA MS risk alleles, a similar trend, although non
significant (p = 0.06), was still observed (wGRS mean: 6.784 in
OCB+ vs. 6.686 in OCB2). Finally, to search for new associations,
not yet correlated with disease susceptibility, we performed a
GWAS with OCB status using the PROGEMUS/PROGRESSO
subset of the IMSGC-WTCCC GWAS [9] as a discovery sample
(Figure 2) to perform a GWAS with OCB status. Replication of the
best signals in the Italian dataset was performed in silico using data
from the previously published GWAS [9] from independent
populations from Scandinavia (Norwegian-Danish-Swedish) (1367
OCB+ and 161 OCB2) and Belgium (317 OCB+ and 39 OCB2).
To select SNPs for replication, an arbitrary significance threshold
(p-value ,1024) was chosen as a balance between sensitivity and
specificity in order to ensure the detection of genuine associations
that may not reach GWAS threshold in our sample set. A total of
89 SNPs were selected (Table S1). After the meta-analysis of the
combined datasets (Italy, Scandinavia and Belgium), the strongest
signal was a non-HLA SNP (rs9320598) on chromosome 6
(p = 9.461027) (Figure 2, Table S1) outside the HLA region
(65 Mb).
Discussion
The percentage of OCB2 patients (12%) in our Italian sample
was in the range of that found in South Europe and OCB status
was clearly associated with carriage of DRB1*15 as in other studies
[1]. The intrathecal synthesis of immunoglobulins, as marked by
OCB status, is observed in the preclinical phase of MS and the
possibility of conversion from negative to positive is low [1],
suggesting that there is a genetic trait predisposing to its
development. Three findings from our data support this hypoth-
esis: 1) DRB1*15 is associated with OCB+; 2) the combination of
non-HLA markers associated with MS susceptibility also showed a
trend for association with the presence of OCB as suggested by our
wGRS, although most of its predictive power comes from
DRB1*15; 3) after meta-analysis of the Italian best associated
markers with two independent data-sets, we found a non-HLA
SNP on chromosome 6 that almost reached GWAS significance.
This SNP maps at 300 kb telomeric to C6orf167/MMS22L, a
gene involved in the regulation of genome stability and DNA
repair [11], and at 400 kb telomeric to KLHL32/KIAA1900, a
gene with still uncharacterized function. Since this association did
not reach genome-wide significance, further independent studies
are needed to confirm this finding. Although it may be premature
to assume that this locus is associated with OCB status, this and
the other findings in our study suggest that genetic factors may be
involved in the development of OCB. OCB status has been
associated in turn with MS prognosis [12]; thus our findings could
provide some clues to clarify the genetic predictors of disease
prognosis.
One possible bias of our study is the selection of MS patients
that underwent lumbar puncture; however their percentage was
high and the clinical characteristics of those with CSF examination
were similar to those without. We cannot exclude that the group of
OCB negative patients represent a peculiar type of MS or even not
MS cases. However, the clinical similarity of OCB+ and OCB2
patients argues against this [13].
In conclusion, our data support the hypothesis that HLA genes
and possibly other non-HLA genes predispose to the development
of OCB.
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